Market Analysts see Akebia Therapeutics Inc. [AKBA] falling to $2. Time to buy?

Related

Akebia Therapeutics Inc. [NASDAQ: AKBA] traded at a low on 04/22/22, posting a -0.65 loss after which it closed the day’ session at $0.47. The company report on April 6, 2022 that Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2022.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022 (SCM22), which will take place on demand and live in Boston on April 6 – 10, 2022.

Abstracts are available online in the SCM22 Abstract and ePoster Gallery: https://cme.kidney.org/spa/courses/resource/2022-spring-clinical-meetings/event/home/posters/browser.

The results of the trading session contributed to over 13357173 shares changing hands. Over the past one week, the price volatility of Akebia Therapeutics Inc. stands at 8.47% while the volatility over the past one month is 20.57%.

The market cap for AKBA stock reached $86.94 million, with 174.65 million shares outstanding and 173.27 million shares in the current float. Compared to the average trading volume of 9.12M shares, AKBA reached a trading volume of 13357173 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Akebia Therapeutics Inc. [AKBA]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKBA shares is $1.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKBA stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Akebia Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 31, 2022. The new note on the price target was released on March 31, 2022, representing the official price target for Akebia Therapeutics Inc. stock. Previously, the target price had yet another drop from $6 to $2, while Mizuho kept a Neutral rating on AKBA stock. On March 31, 2022, analysts decreased their price target for AKBA shares from 10 to 2.

The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.13, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 0.41. The Price to Book ratio for the last quarter was 1.07, with the Price to Cash per share for the same quarter was set at 0.81.

How has AKBA stock performed recently?

Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.36. With this latest performance, AKBA shares dropped by -80.90% in over the last four-week period, additionally sinking by -83.73% over the last 6 months – not to mention a drop of -84.64% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKBA stock in for the last two-week period is set at 21.79, with the RSI for the last a single of trading hit 17.48, and the three-weeks RSI is set at 26.06 for Akebia Therapeutics Inc. [AKBA]. The present Moving Average for the last 50 days of trading for this stock 1.6984, while it was recorded at 0.4766 for the last single week of trading, and 2.4001 for the last 200 days.

Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -124.23 and a Gross Margin at +27.28. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -132.43.

Return on Equity for this stock declined to -174.55, with Return on Assets sitting at -48.36.

Akebia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.

Insider trade positions for Akebia Therapeutics Inc. [AKBA]

There are presently around $46 million, or 57.10% of AKBA stock, in the hands of institutional investors. The top three institutional holders of AKBA stocks are: BLACKROCK INC. with ownership of 14,124,215, which is approximately 0.51% of the company’s market cap and around 1.40% of the total institutional ownership; VANGUARD GROUP INC, holding 13,235,669 shares of the stock with an approximate value of $6.25 million in AKBA stocks shares; and STATE STREET CORP, currently with $5.54 million in AKBA stock with ownership of nearly -25.939% of the company’s market capitalization.

Positions in Akebia Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 71 institutional holders increased their position in Akebia Therapeutics Inc. [NASDAQ:AKBA] by around 9,636,607 shares. Additionally, 53 investors decreased positions by around 10,617,869 shares, while 28 investors held positions by with 76,589,349 shares. The mentioned changes placed institutional holdings at 96,843,825 shares, according to the latest SEC report filing. AKBA stock had 28 new institutional investments in for a total of 4,133,212 shares, while 19 institutional investors sold positions of 1,654,988 shares during the same period.